In this conversation, Andres Acosta, MD, PhD, joins series chair Robert F. Kushner, MD, to explore obesity phenotypes as a framework for individualizing care. Dr. Acosta examines how differences in appetite, satiety, energy expenditure, and eating behavior may help explain the wide variation in treatment response — and offers a candid appraisal of how far the science has come and how far it still has to go, since validated predictors of drug response are not yet established.
As the third of four conversations, this segment turns the series’ theme of heterogeneity into a practical lens. After framing why multiple pathways are needed and exploring the biology of amylin, it asks how clinicians might one day match patient to pathway.